Drug Profile
CEN 209
Alternative Names: SN 30000Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Auckland UniServices
- Developer Cancer Research UK; Varian Medical Systems
- Class Antineoplastics; Radiation-sensitising agents; Reducing agents
- Mechanism of Action DNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in United Kingdom
- 25 May 2011 Preclinical trials in Solid tumours in United Kingdom (unspecified route)